Remove 2027 Remove Healthcare Remove Patient-Centered Remove Provider
article thumbnail

Governor’s 2025-26 May Revision Proposes Major Cuts to Healthcare and Undermines Medi-Cal Expansion Commitments

California Academy of Family Physicians (CAFP)

However, for individuals who do not qualify for federal Medicaid funding—such as most undocumented immigrants—the federal government does not provide matching funds, even when those individuals meet income eligibility requirements. The May revision proposes eliminating and suspending much of this funding.

article thumbnail

From Surgeries To Keeping Company: The Place Of Robots In Healthcare

The Medical Futurist

Here’s our overview to understand robotics in healthcare better so that everyone can prepare for the appearance of mechanic helpers in medical facilities. For this reason, we collected here the most useful robots in healthcare. By 2027, global surgical robotics sales are expected to reach $14.8

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Proposed LDT Rule Raises Many Questions but Provides Few Answers

FDA Law Blog

The brevity of this change belies the foreseeably seismic impact of FDA regulation of clinical laboratories on the healthcare system. What, if any, unintended consequences may result from the proposed phaseout policy to certain patient populations (for example, Medicare beneficiaries, rural populations, etc.)

article thumbnail

Wearables, Sensors, and Apps Part 1 – Updates on FDA’s PDUFA VII Goals for the Use of Digital Health Technologies in Drug and Biological Product Development

FDA Law Blog

A DHT is considered “a system that uses computing platforms, connectivity, software, and sensors for healthcare and related uses.” FDA has made good progress on these initial goals, providing updates on the first four on the Digital Health Technologies (DHTs) for Drug Development website.

article thumbnail

“TAP Dancing” Towards Faster Device Commercialization: CDRH’s Total Product Life Cycle Advisory (“TAP”) Program

FDA Law Blog

He highlighted the following key features of TAP: An Innovative Approach To provide proactive support and guidance to medical device manufacturers, FDA has introduced a new CDRH position known as the “TAP Advisor.” Also, it is unclear which office within CDRH appoints the TAP Advisor, e.g., center-level, OPEQ-level, or division-level.